- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05642351
Autobiographical Specificity (ESAD)
April 2, 2026 updated by: Nantes University Hospital
Autobiographical Specificity in Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia
Autobiographical memory is diminished in patients with Alzheimer's Disease and those with behavioral variant of frontotemporal dementia, and research has focused on the hampered ability of patients in retrieving specific memories.
However, this study proposes a detailed methodology to provide a qualitative analysis of autobiographical specificity.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Patients with Alzheimer's Disease and those with behavioral variant of frontotemporal dementia will be invited to retrieve autobiographical memories.
Memories will be analyzed and categorized into specific, categoric, extended, or semantic autobiographical retrieval.
Study Type
Observational
Enrollment (Actual)
39
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Nantes, France
- EL HAJ Mohamad
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Sampling Method
Non-Probability Sample
Study Population
All participants will be recruited through the active file of memory consultations of the "memory resource and research center" (CMRR) of the Nantes University Hospital.
Description
Inclusion Criteria:
- Alzheimer' disease or avioral variant of frontotemporal dementia
- No opposition from the patient to be included in the study
- For Alzheimer's patients: a score of more than 24 out of 30 on the Mini Mental State Examination (McKhann et al., 1984)
Exclusion Criteria:
- Other psychiatric/neurological disorders
- Minor patients
- Adults under guardianship or protection.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Alzheimer's Disease
recruited according to criteria by National Institute on Aging (McKhann et al., 2011).
|
The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:
|
|
Behavioral variant of frontotemporal dementia
recruited following criteria by Rascovsky et al. (2011)
|
The analysis of the specificity of Autobiographical Recall will be done through the following scale, developed for the study:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Autobiographical specificity
Time Frame: 40 minutes
|
We will apply the method by Raes et al. (2007) to assess whether each retrieved event refers to a: specific event, categorical event, extended event, or semantic event
|
40 minutes
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 3, 2023
Primary Completion (Actual)
March 6, 2026
Study Completion (Actual)
March 6, 2026
Study Registration Dates
First Submitted
November 22, 2022
First Submitted That Met QC Criteria
November 30, 2022
First Posted (Actual)
December 8, 2022
Study Record Updates
Last Update Posted (Actual)
April 3, 2026
Last Update Submitted That Met QC Criteria
April 2, 2026
Last Verified
April 1, 2026
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Mental Disorders
- Metabolic Diseases
- Neurocognitive Disorders
- Dementia
- Tauopathies
- Neurodegenerative Diseases
- TDP-43 Proteinopathies
- Proteostasis Deficiencies
- Frontotemporal Lobar Degeneration
- Nutritional and Metabolic Diseases
- Alzheimer Disease
- Frontotemporal Dementia
Other Study ID Numbers
- RC22_0626
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alzheimer Disease
-
ProgenaBiomeWithdrawnAlzheimer Disease | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3 | Alzheimer Disease 4 | Alzheimer Disease 7 | Alzheimer Disease 17 | Alzheimer Disease 5 | Alzheimer Disease 6 | Alzheimer Disease 8 | Alzheimer Disease 10 | Alzheimer... and other conditionsUnited States
-
Cognito Therapeutics, Inc.Active, not recruitingCognitive Impairment | Dementia | Alzheimer Disease | Mild Cognitive Impairment | Cognitive Decline | Alzheimer Disease, Early Onset | Alzheimer Disease, Late Onset | MCI | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Cognitive Impairment, Mild | Alzheimer Disease 1 | Dementia, Mild | Alzheimer... and other conditionsUnited States
-
Stanford UniversityNot yet recruitingMCI With Increased Risk for Alzheimer Disease | Alzheimer s DiseaseUnited States
-
University of California, Los AngelesRecruitingAlzheimer Disease | Dementia Alzheimer Type | Alzheimer&Amp;#39;s Disease (AD) | Alzheimer&Amp;Amp;#39;s Disease | Mild Alzheimer&Amp;Amp;#39;s Disease | Moderate Alzheimer&Amp;Amp;#39;s Disease | Alzheimer&Amp;#39;s DementiaUnited States
-
AphiosNot yet recruitingDementia | Alzheimer Disease 1 | Alzheimer Disease 2 | Alzheimer Disease 3
-
Heinrich-Heine University, DuesseldorfNot yet recruitingEarly Onset Alzheimer Disease | Alzheimer Disease (AD)Germany
-
Johns Hopkins UniversityNational Institutes of Health (NIH)Not yet recruiting
-
Xuanwu Hospital, BeijingEnrolling by invitation
-
University Hospital, GrenobleRecruiting
-
Fujian Medical University Union HospitalRecruitingAlzheimer s DiseaseChina
Clinical Trials on Autobiographical reminder
-
Lancaster UniversityCompletedSuicidal Ideation | Mental Health DisorderUnited Kingdom
-
King's College LondonCompleted
-
University of ValenciaNot yet recruitingControl Group | Training Group
-
Medical Research Council Cognition and Brain Sciences...Completed
-
University Hospital, Strasbourg, FranceCompletedAutism Spectrum DisordersFrance
-
University Hospital, BordeauxCompletedPituitary Adenoma | Cavernous Sinus MeningiomaFrance
-
ThinkWellUniversity of Oxford; Queen's University, Belfast; The BMJCompleted
-
University Hospital, MontpellierNot yet recruitingBorderline Personality Disorder | Borderline Personality Disorder (BPD)
-
Chinese University of Hong KongCompleted
-
Interactive Research and DevelopmentCompletedSMS | Immunization; Infection